Q1 Earnings Forecast for CAPR Issued By HC Wainwright

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a research note issued on Friday, March 13th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of ($0.59) for the quarter. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

CAPR has been the topic of a number of other reports. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday. Piper Sandler restated an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday. UBS Group set a $50.00 target price on Capricor Therapeutics in a report on Monday, December 15th. Wall Street Zen downgraded Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Capricor Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $46.09.

Capricor Therapeutics Stock Performance

CAPR stock opened at $30.50 on Monday. The company’s fifty day moving average price is $25.70 and its 200-day moving average price is $16.66. Capricor Therapeutics has a one year low of $4.30 and a one year high of $40.37. The company has a market capitalization of $1.69 billion, a PE ratio of -13.50 and a beta of 0.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Wednesday, March 18th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its position in Capricor Therapeutics by 12.4% during the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 557 shares during the period. ACT Capital Management LLC purchased a new stake in shares of Capricor Therapeutics in the 4th quarter worth approximately $43,000. Nuveen LLC boosted its stake in shares of Capricor Therapeutics by 2.1% during the fourth quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock valued at $2,625,000 after purchasing an additional 1,878 shares in the last quarter. State of Wyoming boosted its stake in shares of Capricor Therapeutics by 76.0% during the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 1,913 shares in the last quarter. Finally, GoalVest Advisory LLC purchased a new position in Capricor Therapeutics during the fourth quarter valued at approximately $59,000. 21.68% of the stock is currently owned by institutional investors.

More Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA review resumed and a new PDUFA/decision date was set for Deramiocel — a major regulatory catalyst that can materially re‑rate the stock if approval looks likely. Capricor: Moving To ‘Buy’ Rating As New PDUFA Date Is Set For Deramiocel
• Positive Sentiment: Late‑breaking HOPE‑3 Phase 3 data presented at the MDA conference showed significant functional benefits for Deramiocel in DMD, supporting the therapy’s efficacy profile heading into the review. HOPE‑3 Data Release
• Positive Sentiment: Company financial positioning: Capricor highlights roughly $318M cash on hand and frames the FDA milestone as supporting potential commercialization, which reduces near‑term dilution risk. Cash & Commercialization Note
• Positive Sentiment: Analyst support has increased: B. Riley raised its price target to $63 (buy), Piper Sandler reaffirmed overweight and lifted its target to $58, and HC Wainwright reiterated buy — these upgrades boost conviction among buy‑side investors. Benzinga Coverage (B. Riley / Piper Sandler) HC Wainwright Reiterate
• Neutral Sentiment: Management tone is bullish on the regulatory path (CEO pushed back against the idea of only a conditional approval), which supports investor confidence but is not definitive on outcome. CEO Comment
• Negative Sentiment: Q4 results disappointed: EPS of ($0.62) missed consensus (~$0.51) and the loss widened year‑over‑year, prompting intraday selling and headlines calling out the miss. That weakens near‑term sentiment despite the regulatory upside. Q4 Earnings Miss Benzinga: Stock Slides

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.